BACARDI-LIMITED
13.2.2020 14:17:09 CET | Business Wire | Press release
Family-owned Bacardi Limited has been doing the right thing for its people, its community and the planet more than 158 years. Today, the company released its fiscal year 2019 Good Spirited Corporate Responsibility (CR) Report to provide open and transparent communications in how it’s championing commitments within its CR pillars of marketplace , people , environment , responsible sourcing , and philanthropy and community investment . From responsible drinking efforts, to driving a positive and diverse culture, to hurricane disaster relief and reducing the impact on natural resources, the Good Spirited Corporate Responsibility Report outlines progress in fiscal year 2019, alongside commitments for the future. This marks the 12th annual CR report issued by privately-held Bacardi Limited.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005465/en/
“Being family-owned for seven generations allows us to stay true to our values of being fearless to innovate, behaving like family to each other and our communities, and exhibiting founders mentality in always doing the right thing -- particularly towards making the world a more sustainable, safe and transparent place,” says Rick Wilson, Senior Vice President of Corporate Responsibility at Bacardi. “It’s extremely gratifying to see us achieve key milestones, in some cases ahead of time, and to continuously pursue new goals and set higher standards for the future.”
The report outlines the overall marketplace for spirits and addresses the responsibility Bacardi has in promoting responsible drinking practices and targeting our marketing only to legal age drinkers. With the evolution of digital marketing, the company has doubled down efforts to enforce safeguards to limit minors from seeing alcohol marketing online. Bacardi has achieved 79% compliance in establishing these safeguards with an aim to be 100% compliant by 2020. Bacardi has also been an early mover in the space of nutrition transparency, with the launch of a Bacardi nutrition website in key markets giving consumers more information about what they’re drinking including calories and allergens.
The vibrant, warm and entrepreneurial culture at Bacardi is reflected in the exceptional employee engagement with the global internal survey showing 89% of employees saying they are “proud to work for the company.” External perception of the company is also positive as Bacardi Limited was named among the most reputable companies in the world as part of the annual Global RepTrak® 100 list compiled by the Reputation Institute (RI) and published in Forbes. Ranked at #87, Bacardi Limited climbed two spots and has made the annual global list seven consecutive times.
Bacardi believes in the inherent value that can be created when you bring together a diverse and inclusive community and workplace. Helping female talent at Bacardi, and within our community, is among the many causes championed by the company through its Global Reflections program. The company has made considerable headway with women making up 44% of North America and 40% of Europe – which represent the two largest regions of the business. In addition, 37% of the leadership positions in the company were held by women in fiscal year 2019 and the company continues to work towards narrowing the gender gap.
Bacardi continues to push the boundaries with aspirations to be the world’s most environmentally responsible global spirits company. Finding a second life for all waste is a priority and the company’s production facilities have achieved 99.6% of waste diversion. Despite increases in production, the company has been able to reduce greenhouse gas emissions from operations by 20% and cut water consumption by almost 10% through efficiencies in assets utilization. It is also committed to the long-term sustainability and responsible sourcing of sugarcane, agave, wheat, botanicals, and other natural resources needed to craft its world-class premium products. Already 98.4% of the sugarcane-derived products used in BACARDÍ® rums are sourced from suppliers certified by Bonsucro, with the goal of reaching 100% by the end of fiscal year 2020, three years ahead of initial targets. The company also achieved ECOCERT certification for 50% of botanicals for BOMBAY SAPPHIRE® gin with a goal to certify 100% of the botanicals in the coming year. With an eye for the future and always pushing to do greater good, Bacardi has defined a long-term plan to reduce greenhouse gas emissions by 20% and water consumption by 25% by fiscal year 2024.
Going beyond the company to care for the community is part of the DNA at Bacardi since its inception in 1862. Bacardi, together with Mercy Corp, continues to support the long-term recovery efforts in Puerto Rico, where BACARDÍ rum is produced, after devastation from Hurricanes Maria and Irma in 2017, providing habitat rehabilitation, financial grants, business training, and marketing support to 243 businesses on the island.
To read more about Corporate Responsibility within Bacardi, check out the complete FY19 Corporate Responsibility Report, which encompasses April 1, 2018 – March 31, 2019, online https://www.bacardilimited.com/corporate-responsibility/ .
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka.
Founded more than 158 years ago, in Santiago de Cuba on February 4, 1862, family-owned Bacardi currently employs more than 7,000, operates more than 20 production facilities, including bottling, distilling and manufacturing sites in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Instagram , LinkedIn and Twitter .
Enjoy Responsibly.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
